Science Explorer Back to mapMap
Discussion
Company · Marseille · France

Qiagen (France)

qiagen.com/frROR OpenAlex
Research works
1
▼ 100% vs 2018-21
Citations
39
33.1 per fractional work
Top-10% rate
5.1%
all institutions 10.0%
Open access
67%
world 40%
International
38%
world 18%
Qiagen (France)

Not ranked overall: Qiagen (France) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Qiagen (France) work in?

In all years, 75% of research at Qiagen (France) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (75%), Biochemistry, Genetics and Molecular Biology (25%).

Health Sciences: 1 fractional works · 75.0% of its workMedicine: 1 fractional works · 75.0% of its workLife Sciences: 0 fractional works · 25.0% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 25.0% of its workALL ITS WORKQiagen (France)1fractional works, all years
Life Sciences25%Health Sciences75%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Medicine175.0%
    1. Biochemistry, Genetics and Molecular Biology025.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Qiagen (France)?

The most cited paper from Qiagen (France) is "Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study" (Jelena V. Jovanovic et al., 2013), with 107 citations. Next come "Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay" (50) and "A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma" (45).

Most cited papers
#PaperReleasedCitations
1 Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study Jelena V. Jovanovic et al. · Leukemia Open access 17 Jul 2013 107
2 Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay Delphine Mouttet, Marick E Lae, Martial Caly et al. · PLoS ONE Open access Feb 2016 50
3 A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma Aurélie Catteau, Hélène Girardi, Florence Monville et al. · Acta Neuropathologica Communications Open access 2 Jun 2014 45
4 Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells Nanor Sirab, G. Robert, Virginie Fasolo et al. · International Journal of Molecular Sciences Open access 10 Jul 2013 36
5 Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis Éric Lippert, Olivier Mansier, Marina Migeon et al. · Haematologica Open access 16 May 2014 30
All 9 most cited papers, with filters and sorting

Which research topics does Qiagen (France) publish most on?

By volume: Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, HER2/EGFR in Cancer Research and Chronic Myeloid Leukemia Treatments.

Breast Cancer Treatment Studies: 0 fractional worksBreast Lesions and Carcinomas: 0 fractional worksHER2/EGFR in Cancer Research: 0 fractional worksChronic Myeloid Leukemia Treatments: 0 fractional worksMeningioma and schwannoma management: 0 fractional worksBrain Metastases and Tre…0Brain Metastases and Treatment: 0 fractional worksGlioma Diagnosis and Treatment: 0 fractional worksAcute Myeloid Leukemia Research: 0 fractional works
Cancer ResearchPathology and Forensic MedicineOncologyHematology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Breast Cancer Treatment Studies Cancer Research 0 works
  2. 2 Breast Lesions and Carcinomas Pathology and Forensic Medicine 0 works
  3. 3 HER2/EGFR in Cancer Research Oncology 0 works
  4. 4 Chronic Myeloid Leukemia Treatments Hematology 0 works
  5. 5 Meningioma and schwannoma management Epidemiology 0 works
  6. 6 Brain Metastases and Treatment Pulmonary and Respiratory Medicine 0 works
  7. 7 Glioma Diagnosis and Treatment Genetics 0 works
  8. 8 Acute Myeloid Leukemia Research Hematology 0 works
  9. 9 Advances in Oncology and Radiotherapy Radiology, Nuclear Medicine and Imaging 0 works
  10. 10 Advanced Glycation End Products research Clinical Biochemistry 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available66.7%not open33.3%

World: 40% of research is openly available.

with international co-authors38.3%domestic only61.7%

World: 18% is written across borders.

How has Qiagen (France)'s research output changed?

Output in 2022-2025 was 100% lower than in 2018-2021.

2015

Other research institutions in Marseille

All research institutions in Marseille

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Qiagen (France). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.